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ABSTRACT
Pokeweed antiviral protein (PAP) is a glycosidase
of plant origin that has been shown to depurinate
some viral RNAs in vitro. We have demonstrated
previously that treatment of Brome mosaic virus
(BMV) RNAs with PAP inhibited their translation in
a cell-free system and decreased their accumulation
in barley protoplasts. In the current study, we map
the depurination sites on BMV RNA3 and describe
the mechanism by which replication of the viral RNA
is inhibited by depurination. Specifically, we demon-
strate that the viral replicase exhibited reduced affi-
nity for depurinated positive-strand RNA3 compared
with intact RNA3, resulting in less negative-strand
product. This decrease was due to depurination
within the intergenic region of RNA3, between
ORF3 and 4, and distant from the 3’ terminal core
promoter required for initiation of negative-strand
RNA synthesis. Depurination within the intergenic
region alone inhibited the binding of the replicase
to full-length RNA3, whereas depurination outside
the intergenic region permitted the replicase to initi-
ate negative-strand synthesis; however, elongation
of the RNA product was stalled at the abasic nucleo-
tide. These results support a role of the intergenic
region in controlling negative-strand RNA synthesis
and contribute new insight into the effect of depur-
ination by PAP on BMV replication.
INTRODUCTION
Brome mosaic virus (BMV) is a positive-strand RNA
plant virus with a genome comprised of three RNAs,
designated RNA1, RNA2 and RNA3 (1–3). RNA1
encodes 1a protein with methyltransferase and helicase
activity and RNA2 encodes 2a protein bearing motifs of
an RNA dependent RNA polymerase (4–6). Both 1a and
2a proteins are essential components of the viral replicase
complex, which also contains several host proteins (7,8).
RNA3 is dicistronic; the 50 proximal gene encodes a move-
ment protein that is translated directly from RNA3,
whereas the 30 proximal gene is expressed from a subge-
nomic RNA4 to produce the coat protein (9–11).
Replication of BMV RNAs occurs through a negative-
strand RNA intermediate and is performed by the viral
replicase complex (2,3).
The cis-acting elements involved in eﬃcient replication
of BMV RNAs have been characterized both in vitro, with
the isolated replicase, and in vivo, by either transfecting
modiﬁed RNAs into plant protoplasts or transforming
them into yeast cells (12–14). With speciﬁc reference to
RNA3, these studies have uncovered that the 30 UTR of
this RNA, which forms a tRNA-like structure, bears a
stem-loop C that binds the BMV replicase and directs
negative-strand synthesis (15,16). In addition, a minimal
promoter sequence located at the 30-end of negative-strand
RNA3 interacts with the replicase to direct positive-strand
initiation (12,17). The approximately 250-nucleotide inter-
cistronic region of RNA3 contains an enhancer required
for replication (18), and a cis-acting sequence essential for
replicase assembly in yeast (19,20).
We have shown previously that a glycosidase isolated
from the plant Phytolacca americana depurinates BMV
RNAs in vitro (21). Known as pokeweed antiviral protein
(PAP), this enzyme reduces the titer of several diﬀerent
viruses (22–24). The antiviral activity was initially attrib-
uted to host cell toxicity caused by rRNA depurination, as
PAP is also a ribosome-inactivating protein (25,26).
However, we and others have demonstrated the ability
of PAP to directly depurinate viral RNAs (21,27). In addi-
tion, pretreatment of only BMV RNA3 with PAP, prior to
transfection into barley protoplasts with RNAs 1 and 2,
resulted in diminished accumulation of all BMV RNAs.
An artiﬁcial RNA template containing the minimal bind-
ing site for the viral replicase showed that substitution
of nucleotides with abasic residues, to mimic depurina-
tion, caused the replicase to stall during elongation (28).
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activity of the viral replicase using the full-length RNA3
as template. We demonstrate that depurination within the
intergenic region of the positive-strand RNA3 inhibited
the binding of the replicase complex and decreased the
synthesis of RNA both in vitro and in vivo. Therefore,
RNA sequence distant from the replicase initiation site
for negative-strand synthesis inﬂuenced replicase activity.
This work provides new understanding of how depurina-
tion contributes to the antiviral activity of PAP and also
illustrates the utility of this glycosidase to characterize the
binding requirements of the viral replicase to its template
BMV RNA3.
MATERIALS AND METHODS
Treatment of BMVRNA3 with PAP
Capped, in vitro transcripts of BMV RNA3 (1.5pmol)
were incubated with PAP (34pmol) in RIP buﬀer
(60 mM KCl, 10mM Tris–HCl, pH 7.4, 10mM MgCl2)
to a ﬁnal volume of 50ml for 30min at 308C. Untreated
RNA3 was incubated in the same manner in the absence
of PAP. Following incubation, RNA was extracted, pre-
cipitated in 100% ethanol and resuspended in DEPC-
treated water.
Replicase assay
A fraction enriched for the BMV replicase was isolated
by gel chromatography from infected barley leaves as
described previously (29). Each replicase assay consisted
of a 40ml reaction containing 50mM sodium glutamate,
pH 8.2, 12mM MgCl2, 8mM DTT, 1mM ATP, 1mM
GTP, 1mM UTP, 0.4% Triton X-100, 4mCi [a
32P]-CTP
(10mCi/ml), 1.5pmol PAP-treated or untreated BMV
RNA3, and 14ml of RdRp fraction. Following incubation
for 90min at 308C, the reaction products were extracted
and precipitated with 6 volumes 100% ethanol, 0.4M
ammonium acetate, and 10mg of glycogen. The RNA pro-
ducts were separated in 7M urea/4.5%, 12% or
20% acrylamide gels, dried and visualized by exposure
to X-ray ﬁlm.
Assessment of RNA3 integrity
PAP-treated and untreated BMV RNA3s (3pmol) were
incubated in replicase buﬀer only (50mM sodium gluta-
mate, pH 8.2, 12mM MgCl2, 8mM DTT, 1mM ATP,
1mM GTP, 1mM UTP, 0.4% Triton X-100) or in repli-
case buﬀer containing RdRp for 30min at 308C. Aliquots
were removed at various time points (0, 50 and 80min)
and RNA was separated in a 7M urea/4.5% acrylamide
gel and transferred to nylon membrane. To detect BMV
RNA3, the membrane was probed with a 200-nucleotide
radiolabeled RNA complementary to the 30 end of BMV
RNA3 (pB3HE1; 28). Blots were visualized by exposure to
X-ray ﬁlm.
Mapping of BMVRNA3 depurination sites
Capped, in vitro transcripts of BMV RNA3 were treated
with PAP or untreated as described above, and primer
extension analysis was used to detect depurination sites.
Reverse primers spanning approximately every 200 nucleo-
tides of BMV RNA3 were 50 end-labeled with T4 polynu-
cleotide kinase for 1h at 378C. BMV RNA3 (0.3pmol)
was incubated with 2.5 10
5 cpm of cDNA3 probe and
extended with reverse transcriptase for 25min at 488C.
To identify the sites of depurination, deoxynucleotide
sequencing of BMV cDNA3 was conducted with the
same reverse primers used for primer extension analysis.
The samples were separated in a 7M urea/6% acrylamide
gel and bands were visualized by exposure to X-ray ﬁlm.
Sites of depurination were mapped onto the predicted
secondary structure of RNA3 using mfold analysis (30).
Template competition assay
This assay was performed as described for the replicase
assay except that 12.5nM of PAP-treated or untreated
BMV RNA3 in vitro transcripts, directing the synthesis
of full-length product, were used as template in the
RdRp reaction 10min prior to the addition of 9, 18 or
36 nM of competitor RNA, directing the synthesis of a
200-nucleotide product of the 30 end of RNA3. The RNA
products were extracted, precipitated and resuspended as
described for the replicase assay. The products were sepa-
rated in a 7M urea/4.5% acrylamide gel, dried and visual-
ized by exposure to X-ray ﬁlm. The amount of label
incorporated into newly synthesized RNAs was quantiﬁed
with a phosphorimager.
Dot blot assay
The BMV replicase assay was performed as described
above using PAP-treated or untreated BMV RNA3
(0.4pmol) as template and increasing amounts of BMV
replicase fraction (0, 5, 10, 15 or 20ml). Following incuba-
tion for 20min at 308C, the assay mixture was ﬁltered
through a nitrocellulose membrane that was underlaid
with a nylon membrane using a dot-blot apparatus. The
membranes were probed with an RNA complementary to
the 30 end of BMV RNA3 (pB3HE1; 28). The amount of
RNA3 retained on the ﬁlter was visualized by exposure to
X-ray ﬁlm.
Filter-binding assay
Capped, internally labeled, BMV RNA3 in vitro tran-
scripts were treated with PAP or untreated as described
above. Transcripts were incubated with increasing
amounts of BMV replicase fraction (0, 5, 10, 15 or 20ml)
for 2h before passing the mixture through a nitrocellulose
ﬁlter. The amount of retained labeled RNA was deter-
mined by scintillation counting and corrected by subtract-
ing background counts in the absence of replicase.
Generationof BMVRNA3 constructs
RNA ligase catalyzes a phosphodiester bond between the
50 acceptor RNA terminating in a 30 hydroxyl and the 30
donor RNA terminating in a 50 monophosphate. Regions
of BMV RNA3 were incubated with tobacco acid pyro-
phosphatase to produce the donor RNAs in a 50ml reac-
tion containing 5ml1 0  TAP Buﬀer (0.5M sodium
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0.1% Triton X-100), 1ml 100mM ATP, 20 units RNase
inhibitor, 10 units TAP and incubated for 1h at 378C.
Following incubation, RNA was extracted, precipitated
in 100% ethanol and resuspended in DEPC-treated
water. Regions of BMV RNA3 serving as the donor
RNAs were ligated to the regions of RNA3 serving as
the acceptor RNAs to produce full-length BMV RNA3.
Ligation was performed in a 50ml reaction: 5ml1 0  T4
RNA Ligase Buﬀer (600mM potassium acetate, 330mM
Tris–acetate, pH 7.8, 100mM magnesium acetate, 5mM
DTT), 15 units T4 RNA ligase, 20 units RNase inhibitor
and incubated for 16h at 168C. Following incubation,
RNA was extracted, precipitated in 100% ethanol and
resuspended in DEPC-treated water. Ligated BMV
RNA3 was separated in a 7M urea/4.5% acrylamide gel
and probed by northern blot analysis as described above
to visualize full-length RNA3 following ligation. Full-
length RNA, pooled from several experiments, was
excised and eluted from the gel and RT–PCR was per-
formed followed by sequencing to ensure that the correct
alignment of fragments was achieved. Diﬀerent types of
RNA3 constructs (0.5pmol) were used to perform repli-
case assays. For the type I construct, the acceptor RNA
consisting of nucleotides 1–1913 of BMV RNA3 was incu-
bated with PAP in RIP buﬀer for 30min at 308C. For the
type II construct, the donor RNA, which consisted of
nucleotides 92–2113 of BMV RNA3, was incubated with
PAP, and for the type III construct, the intergenic region
consisting of nucleotides 1004–1246 of BMV RNA3 was
incubated with PAP. To test the eﬀect of depurination
outside the intergenic region yet within the 30 UTR, 400
nucleotides of the 30 end of RNA3 (1713–2113) were incu-
bated with PAP prior to ligation to the remaining 50
region.
Isolationand transfection of barley protoplasts
Protoplasts were isolated from 7-day-old barley leaves
by enzymatic digestion as described previously (31).
Protoplasts (3 10
5) were transfected with either type I,
II or III BMV RNA3 constructs along with BMV RNA 1
and RNA 2 (0.5mg each RNA) using PEG 1500 as
described (28), and incubated at 258C under constant
ﬂuorescent light (165mmol/m
2/s) for 18h.
Isolationof protoplastnucleic acidandnorthern blot analysis
Following the 18h incubation, protoplasts were pelleted at
1000 g for 20s and total nucleic acid was isolated by
adding 300ml of Extraction Buﬀer (2  TE, 1% SDS)
and 300ml phenol:chloroform:isoamyl alcohol. The aqu-
eous layer was re-extracted and nucleic acid was precipi-
tated with 100mlo f8 MN H 4OAC and 1ml of 95%
ethanol and resuspended in DEPC-treated water. Equal
amounts of total nucleic acid were separated in a 7M
urea/4.5% acrylamide gel and transferred to nylon mem-
brane. To detect BMV RNAs, the membrane was probed
with a 200-nucleotide radiolabeled RNA complementary
to the 30 end of all BMV RNAs and 28S rRNA was also
probed as a loading control (28). Blots were visualized by
exposure to X-ray ﬁlm.
RESULTS
Effect of PAPon negative-strand RNA3 synthesis
We have shown previously that in vitro PAP-treatment of
RNA3 followed by transfection into protoplasts with
RNAs 1 and 2 resulted in decreased accumulation of all
BMV RNAs (28). To determine if inhibition of replicase
activity contributed to this decrease, PAP-treated RNA3
transcript was used as template in an enzyme assay with
the BMV replicase complex. Substantially less product
was synthesized from PAP-treated template compared
with untreated RNA3 (Figure 1A). During this assay, ali-
quots were removed and the amount of radiolabeled RNA
was found to be consistently greater from untreated tem-
plate, compared with the PAP-treated RNA3 (Figure 1B).
To address the possibility that either PAP treatment itself,
or subsequent incubation with the replicase complex
(which could have contained a co-puriﬁed nuclease),
may have caused preferential degradation of the template,
RNA3, treated or untreated, was incubated over a time
course with either replicase complex or buﬀer. Northern
blot analysis indicated no notable diﬀerence in the visual
integrity of the RNA from treated or untreated samples
(Figure 1C).
Sites of depurinationin BMV RNA3
To investigate whether this decrease in RNA synthesis
correlated with depurination of the RNA3 template, we
mapped the discrete depurination sites along full-length
BMV RNA3. The line drawing, illustrating the coding
and regulatory regions of this RNA, indicates locations
of depurination and the speciﬁc nucleotides identiﬁed by
primer extension analysis (Figure 2A and B). Depurinated
nucleotides were found consistently in single-stranded
regions of the RNA, as predicted by mfold analysis (30).
Interestingly, none of these sites was contained within the
core promoter of the 30 tRNA-like region where synthesis
of negative-strand RNA3 initiates. Speciﬁcally, the stem
loop C of the 30 tRNA region located within nucleotides
2039–2069 is required for replicase binding and the term-
inal CCA sequence plus approximately ﬁve neighboring
nucleotides is recognized by the replicase complex as the
site of negative strand initiation (16,32). The decreased
amount of RNA3 product synthesized from PAP-treated
template suggested that replicase activity was controlled
by regions of RNA3 outside these 30 sequences known to
be recognized by the replicase complex.
The lack of truncation products observed following the
replicase assay suggested that rather than initiating on all
strands of RNA3 and terminating prematurely when
encountering a missing base, the replicase likely only initi-
ated on intact strands of RNA, resulting in full-length pro-
duct. The observation that some intact product RNA was
formed from the PAP-treated template agrees with our ear-
lier ﬁndings that less than 100% depurination occurs to
RNA treated with PAP at physiological concentration;
therefore, some strands of template RNA remained intact
following incubation with PAP. The absence of truncated
RNA is in contrast to our previous work showing that
abasic nucleotides artiﬁcially introduced upstream of a
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stall at the missing base (28). We hypothesize that the reg-
ulatory regions contained within full-length RNA3 either
aﬀected replicase-promoter binding or initiation of RNA
synthesis, even though no bases known to be essential for
replicase activity in vitro were depurinated.
Effect ofPAP on replicase complex binding
To conﬁrm that the replicase complex exhibited greater
activity for untreated RNA compared with the equivalent
PAP-treated template, a competition assay was performed
in which the enzyme complex was incubated with either
template in the presence of increasing concentration of the
30-terminus of BMV RNA3, which has been shown pre-
viously to act as competitor template for the replicase (32).
This 200-nucleotide 30 fragment contains both the pro-
moter and initiator sequences necessary for replicase
binding and RNA synthesis. The amount of competitor
required to decrease RNA synthesis from the full-
length template by 50% (IC50) for PAP-treated RNA3
was 11nM, compared to 33nM for untreated RNA3
(Figure 3A). Therefore, the replicase complex exhibited
less activity for the PAP-treated BMV RNA3 and was
competed away from this template more easily than if
untreated RNA3 was provided.
To further test for interaction of the replicase complex
with BMV RNA3, either PAP-treated or untreated RNA
was incubated with increasing amount of the enzyme
complex, passed through nitrocellulose and probed for
retained RNA3. A greater amount of untreated RNA3
was trapped by the blot compared with PAP-treated
RNA (Figure 3B). As an indicator of the starting
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marker. (B) PAP-treated and untreated BMV RNA3 in vitro transcripts
were incubated with BMV replicase in the presence of radiolabeled
CTP and aliquots were removed at the indicated times. The RNA
products were precipitated and the amount synthesized over time was
quantiﬁed by scintillation counting. Points are means SE for three
separate experiments. Circles represent PAP-treated template RNA3
and squares represent untreated RNA3. (C) A time-course analysis of
the status of PAP-treated BMV RNA3 in vitro transcripts used as
template for the replicase assay and primer extension. PAP-treated
and untreated BMV RNA3 transcripts were incubated with the repli-
case (RdRp) or in buﬀer alone, and aliquots were removed at the
indicated times. RNA was analyzed by northern blot for positive-
strand BMV RNA3.
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Figure 2. In vitro depurination of BMV RNA3 by PAP. (A) Schematic
of BMV RNA3 indicating the sites of depurination by their nucleo-
tide number. The 50 untranslated region (50 UTR; 1–91nt), the open
reading frame of RNA3 (ORF3; 92–1003nt), the intergenic region
(IGR; 1004–1246nt), the open reading frame for RNA4 (ORF4;
1247–1813nt) and the 30 untranslated region (30 UTR; 1814–2113nt)
are also indicated. (B) Representative depurination sites determined by
primer extension. In vitro transcript of RNA3, either PAP-treated or
untreated, was extended with reverse transcriptase using cDNA primers
distributed over the length of the viral RNA. Radiolabeled cDNA
products were separated in a 7M urea/6% acrylamide gel and visua-
lized by autoradiography. The same primers were used to identify the
depurination sites by deoxynucleotide sequencing of BMV DNA3.
Nucleic Acids Research, 2008, Vol. 36, No. 22 7233amount of RNA in each sample, a nylon membrane was
placed under the nitrocellulose and also probed for
positive-strand RNA3. This experiment was complemen-
ted by a traditional ﬁlter-binding assay, which illustrates
that the replicase complex bound to untreated RNA3 to
a signiﬁcantly greater extent relative to PAP-treated
RNA3 (Figure 3C). These results support the competition
assay and indicate that the replicase complex interacted
less with full-length PAP-treated RNA3 compared with
untreated RNA.
Effect of depurinationsites on replicase activity invitro
Our observation that prior treatment of RNA3 with PAP
reduced the accumulation of RNA product and also
reduced the binding of the replicase complex suggested
that depurination outside the deﬁned replicase promoter
and initiation sites within the 30 terminus could aﬀect the
activity of the enzyme complex. To investigate this possi-
bility, PAP-treated regions of RNA3 were ligated to
remaining untreated portions, to regenerate the full-
length RNA. For the type I template, the 30-terminal
200 nucleotides were ligated to the PAP-treated 50 region
of 1913 nucleotides. In addition, two other ligated RNA3
molecules were made, one in which the 50 UTR (92 nucleo-
tides) was untreated and ligated to the 2021 nucleotides
downstream that were ﬁrst incubated with PAP (type II
template), and the third template in which the intergenic
region, comprised of nucleotides 1004–1246, was PAP-
treated and ligated to the 50 and 30 regions (type III tem-
plate), as illustrated in Figure 4A. Each fragment treated
with PAP was assessed by primer extension analysis to
conﬁrm the expected depurination sites prior to ligation
(data not shown). These ligated RNAs were then used as
templates in the replicase assay, to determine whether
depurination outside the 50 and 30 termini could inﬂuence
replicase activity. Decreased RNA synthesis was observed
with the type I template; therefore, depurination upstream
of the characterized replicase binding site at the 30 end
inhibited replicase activity (Figure 4B). Results of the
replicase assay using the type II template indicated that
depurination downstream of the 50 UTR also inhibited
replicase activity. The decrease in RNA product seen
from prior PAP treatment of the 50 region in type I tem-
plate and the 30 region in type II template suggested
that depurination within the intergenic region may aﬀect
replicase activity. To assess this possibility, type III tem-
plate was designed to allow PAP treatment only within
the intergenic region of RNA3, prior to its ligation to
the 50 and 30 regions. The observed decrease in amount
of RNA3 product indicated that depurination solely
within the intergenic region reduced replicase activity
(Figure 4C).
Effect of depurinationlocation on replication inbarley
protoplasts
Given our current observation that depurination distant
from the replicase-binding site on the 30 end of positive-
strand RNA3 could diminish production of RNA in vitro,
we investigated whether the same ligated RNAs could
alter replication of BMV in vivo. Thus, each type of ligated
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Figure 3. Replicase interaction with PAP-treated RNA3. (A) PAP-
treated and untreated BMV RNA3 in vitro transcripts were used
as template RNA with increasing concentration of the 30 end RNA3
competitor RNA in the replicase assay. Radiolabeled products were
separated in a 7M urea/4.5% acrylamide gel and visualized by
autoradiography. (B) PAP-treated and untreated BMV RNA3 in vitro
transcripts were incubated with increasing amount of BMV replicase
before passage through a nitrocellulose membrane underlaid by a
nylon membrane. The retained RNA was visualized by probing the
membranes for positive-strand BMV RNA3. (C) Filter-binding assay
of PAP-treated and untreated radiolabeled BMV RNA3 transcripts
incubated with increasing amount of BMV replicase. The amount
of retained RNA was quantiﬁed by scintillation counting and corrected
by subtracting background counts in the absence of replicase.
Points are means SE for three separate experiments. Circles
represent PAP-treated template RNA3 and squares represent untreated
RNA3.
7234 Nucleic Acids Research, 2008, Vol. 36, No. 22RNA3 template was transfected into protoplasts with
untreated RNAs 1 and 2. Subsequent northern blot anal-
ysis of all BMV RNAs showed that type I template, with
the portion of RNA3 upstream of the 30 200-nucleotide
terminus treated with PAP, resulted in diminished replica-
tion of all RNAs (Figure 5A). Transfection of the type II
template, with the RNA treated downstream of the 50
UTR with PAP, also inhibited replication of all RNAs.
Type III template, with only the intergenic region treated
with PAP, also showed decreased accumulation of all
RNAs. Therefore, the levels of in vivo replication in pro-
toplasts were consistent with production of RNA in vitro,
and support our observation that depurination within the
intergenic region of RNA3 inhibits replicase activity. To
address the possible instability of the ligated RNAs in
cells, a time course analysis was conducted for protoplast
samples transfected with either ligated type I template
RNA3 or the original RNA3 transcript. No diﬀerence in
integrity between the two pools of RNAs was observed by
northern blot analysis (Figure 5B).
Effectof depurination withinthe intergenic region
on replicase binding
The decreased replicase activity from RNA3 depurinated
only within the intergenic region suggested that the
replicase does not interact with the RNA template if the
intergenic region is depurinated. To test this hypothesis,
the replicase complex was incubated with template III.
A ﬁlter-binding assay showed that the replicase bound
signiﬁcantly less to RNA3 with depurinated intergenic
region, compared with untreated, ligated RNA3
(Figure 6).
Effectof depurination outsidethe intergenicregion
on replicase activity
Our previous work showed that abasic deoxynucleotides
introduced into a short RNA template containing the
minimal replicase promoter allowed the replicase to initi-
ate RNA synthesis, but that the enzyme complex stalled at
abasic sites (28). To determine if depurinated nucleotides
outside of the intergenic region yet within the 30 UTR
would have the same eﬀect, a portion of the 30 terminus
of RNA3 was incubated with PAP and ligated to the
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PAP-treated or untreated and ligated to the remaining 30 end, which
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type III template, the intergenic region was PAP-treated or untreated
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following the replicase assay using the template RNAs described in (A).
The radiolabeled RNA products were separated in a 7M urea/12%
acrylamide gel and visualized by autoradiography. Std represents radio-
labeled, positive-strand RNA3 in vitro transcript to serve as a size
marker. Values are means of intensities SE for three separate experi-
ments quantiﬁed with a phosphorimager.
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Figure 5. Eﬀect of depurination location on BMV RNA replication
in vivo.( A) Barley protoplasts were transfected with PAP-treated,
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strand BMV RNAs. Std is in vitro transcript of positive-strand RNAs
1, 2 and 3 to serve as size markers. Values are means of intensities for
RNAs 1, 2 and 3 SE for three separate experiments, quantiﬁed with a
phosphorimager. Blots were also probed for 28S rRNA as a loading
control for total RNA. (B) Stability of type I template in barley pro-
toplasts. Type I template (ligated) or non-ligated RNA3 (control) was
transfected into barley protoplasts and aliquots of cells were removed
at the indicated time points. Total protoplast RNA was probed by
northern blot for positive-strand BMV RNA3. The blot was also
probed for 28S rRNA as a loading control for total RNA.
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RNA3. This ligated RNA3 was used as template in the
replicase assay and truncated RNA3 was observed, corres-
ponding in size to replicase stalling at 1971, the most
30 depurinated nucleotide (Figure 7). Though some full-
length RNA3 was synthesized, indicating less than
100% depurination, the presence of a shorter fragment
in PAP-treated RNA3 shows that depurination outside
the intergenic region did permit the replicase to bind to
the template RNA, but caused replicase stalling when the
missing base was encountered. These results agree with
our earlier work using a depurinated minimal promoter
template and demonstrate that omission of the intergenic
region from PAP treatment allowed the replicase to bind
to the 30 end and initiate RNA synthesis.
DISCUSSION
We have shown previously that prior incubation of RNA3
with PAP, followed by transfection with untreated RNA1
and 2 into protoplasts, reduced the level of replication for
all BMV RNAs (28). These results implied that depurina-
tion of RNA3 inhibited the replicase, either by preventing
binding to the template, or inhibiting the synthesis of
RNA. The latter possibility was supported by our obser-
vation that elongation of negative-strand RNA, from a
minimal template suﬃcient for replicase recognition, was
prevented by the presence of artiﬁcially introduced abasic
deoxynucleotides. The replicase initiated but stalled at the
missing base, producing truncated strands of RNA (28).
Here, we have worked with full-length RNA3 to gain a
more biologically relevant understanding of the eﬀect of
depurination on replicase activity. We identiﬁed the exact
sites of depurination on RNA3 and demonstrated that
abasic nucleotides outside the characterized 30 core pro-
moter for negative-strand synthesis inhibited the replica-
tion of RNA, both in vivo and in vitro. Speciﬁcally, we
have determined that depurination within the intergenic
region of RNA3 prevented replicase binding and RNA
synthesis in the absence of depurination elsewhere in the
full-length RNA3. Therefore, we conclude that the inter-
genic region is involved in regulating the synthesis of
negative-strand RNA3.
The results of our competition assay are consistent with
the importance of regions of the RNA outside of the 30
end promoter for negative-strand synthesis. The fact that
the 200-nucleotide 30-terminus of RNA3 functioned as a
competitive RNA indicated that this fragment was suﬃ-
cient for replicase recognition and RNA synthesis initia-
tion. However, in the presence of full-length RNA3, a
3-fold excess of the 30 end promoter was required to
reduce synthesis from full-length template by 50%, indi-
cating that regions of RNA within the full-length strand
enhanced recognition by the replicase. Support for this
conclusion comes from previous work showing that dele-
tion of the 18 base poly(A) tract of the intergenic region
reduced RNA3 accumulation in vivo (33,34). Additionally,
a poly(A) fragment of 16–22 nucleotides competed with a
functional core promoter template for RNA synthesis by
the replicase, indicating that the replicase interacted with
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Figure 7. Eﬀect of depurination 30 of the intergenic region on replicase
activity in vitro.( A) The 30 end (terminal 400 nucleotides) of RNA3 was
PAP-treated or untreated and ligated to the remaining 50 region of
RNA3. The resulting depurination site following PAP treatment is
indicated by the nucleotide number (1971). (B) The RNA3 described
in (A) was used as template in the replicase assay and radiolabeled
products were separated in a 7M urea/6% acrylamide gel and visua-
lized by autoradiography. Marker indicates in vitro transcripts of
known size.
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Figure 6. Replicase binding to RNA3 depurinated within the intergenic
region. The intergenic region of RNA3 was PAP-treated or untreated,
prior to ligation to the remaining 50 and 30 regions of RNA3. A ﬁlter-
binding assay was performed with the ligated, radiolabeled BMV
RNA3 transcripts and increasing amount of BMV replicase. The
amount of retained RNA was quantiﬁed by scintillation counting
and corrected by subtracting background counts in the absence of repli-
case. Points are means SE for three separate experiments. Circles
represent PAP-treated, ligated RNA3 and squares represent untreated,
ligated RNA3.
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tion within this poly(A) sequence of intact RNA3, how-
ever, nucleotides A1219 and G1225 were depurinated and
they were 2 and 6 nucleotides 30 of the poly(A) sequence,
respectively. Therefore, depurination near the poly(A)
sequence likely aﬀected replicase binding. The optimal
sequence for replicase binding to the intergenic region
may well exceed the minimal required sequence, as was
observed with the 30 end of RNA3; namely, that stem
loop C represents the minimal sequence for replicase bind-
ing but that the replicase binds to the 200-nucleotide
tRNA-like sequence approximately 3-fold more than to
stem loop C alone (32). Moreover, diminished negative-
strand synthesis caused by mutation of the initiation
sequence within the 200-nucleotide 30 end of RNA3 was
partially rescued by the addition in cis of 50 sequence of
RNA3 (35). The remaining depurinated nucleotides within
the intergenic region, namely A1006 and A1008, were
located within a 150-base region referred to as the inter-
genic replication enhancer. Deletion of this region has
been shown to decrease RNA3 accumulation in vivo
over 100-fold (36). Taken together, these data strengthen
the importance of the intergenic region for synthesis of
negative-strand RNA3 both in vivo and in vitro. Though
distant in linear sequence, the two pairs of depurinated
nucleotides come in close proximity when viewed in the
secondary structure model for the intergenic region of
RNA3 (37). This model bends the intergenic region essen-
tially in half, bringing A1219 and G1225 physically close
to A1006 and A1008, with all 4 nucleotides in single-
stranded regions, presumably facilitating their depurina-
tion by PAP.
Our work shows that depurination of the intergenic
region reduced synthesis of full-length RNA3, whereas
depurination outside the intergenic region and including
the 30 UTR permitted RNA synthesis but caused the repli-
case to stall at the abasic site. These results are consistent
with the idea that the intergenic region is a regulator of
replicase activity; namely, that when present, the inter-
genic region controls binding and initiation of the repli-
case at the 30 end of RNA3. When absent, as is the case
with minimal RNA templates containing only the core
promoter and initiation site of the 30 end, negative-
strand RNA synthesis occurs regardless, suggesting that
the replicase becomes less discriminatory with regards to
template choice. The biological role of such a regulator
may be to promote initiation from intact templates,
that is, replicase binding and initiation at the 30 end may
be facilitated by ﬁrst or coordinated binding to the inter-
genic region, which may alter template conformation
to favor RNA synthesis. The decreased binding of the
replicase complex to RNA3, in which only the inter-
genic region was depurinated, indicates that synthesis of
negative-strand RNA from a full-length template is depen-
dent on interaction of the replicase complex with the
intergenic region, in addition to its obvious association
with the 30 end of the RNA.
Further support for the role of replicase binding to the
intergenic region comes from previous work showing that
a replicase binding domain is required for RNA synthesis
from structured templates, whereas short, unstructured
RNAs containing only an initiation site without binding
domain are suﬃcient for RNA synthesis by the BMV
replicase (38). A lack of RNA product from the structured
template without binding domain suggested that inhibi-
tion occurred at or before initiation of RNA synthesis.
Our data indicating the absence of truncation products
and decreased replicase binding when only the intergenic
region was depurinated argues that inhibition occurred
prior to initiation, at the step of initial replicase interac-
tion with the template RNA. Full-length BMV RNA3 is
naturally structured, and therefore, would require both a
replicase binding domain and initiation sequence for suc-
cessful synthesis of RNA. We show that apart from the
30 end of RNA3, which contains the stem loop C replicase
core promoter and initiation sequence, the replicase bind-
ing domain of the intergenic region is required for
negative-strand synthesis. It has been postulated that the
replicase scans an RNA template from the 50 end in search
of an initiation site and that intervening secondary struc-
ture, without a replicase binding domain, inhibits this
scanning (38). Therefore, we suggest that binding of the
replicase to the intergenic region guides the replicase to
the 30 end, bypassing natural secondary RNA structure.
Similar scenarios of viral polymerases binding to RNA
sequences distant from initiation sites have been
described. For example, the bacteriophage Qb replicase
binds to an internal RNA segment more than a kilobase
from the 30 end and long-range basepairing interactions
connect the two regions (39). Similarly, inﬂuenza virus
RNA polymerase activity depends on the presence of 50
and 30 genomic viral sequences, suggesting that the poly-
merase binds both ends of the template RNA (40). Our
observations suggest that once binding to the intergenic
region is achieved, the replicase accesses the 30 end of
RNA3 to initiate synthesis of negative-strand RNA.
Our data show that transfection of RNA3, depurinated
only within the intergenic region, along with untreated
RNA1 and 2 into barley protoplasts resulted in decreased
accumulation of all RNAs. This decrease was observed in
positive-strand RNAs; however, given that the replicase
bound less to depurinated RNA3, diminished negative-
strand synthesis likely contributed to the decline in total
accumulation of RNA3. The intergenic region of RNA3
has also been shown essential for replicase complex assem-
bly in yeast (19); therefore, depurination of the RNA3
intergenic region may also decrease replicase activity
in vivo by reducing its assembly, thereby contributing to
the observed decline in synthesis of all RNAs. Transfec-
tion of RNA1 and 2 with RNA3 bearing mutations in
the intergenic region has also been shown to decrease
the accumulation of positive-strand RNA1 and 2 several
fold (41); therefore damage to the intergenic region
of RNA3 may alter RNA1 and 2 levels. In addition
to these possible contributing factors, the decline we
observed in accumulation of positive-strand RNAs 1
and 2 may be due to decreased synthesis of coat protein,
as the level of RNA4 was also diminished, which is synthe-
sized from negative-strand RNA3. Limiting coat protein
would result in decreased encapsidation of viral RNAs,
leaving them susceptible to nuclease degradation.
Nucleic Acids Research, 2008, Vol. 36, No. 22 7237Through identiﬁcation of the nucleotides depurinated
by PAP in full-length RNA3, we have contributed
new insight into the antiviral activity of this enzyme.
Speciﬁcally, we have determined that depurination only
within the intergenic region of positive-strand RNA3
inhibits the binding of the viral replicase, resulting in
decreased initiation of RNA synthesis. Depurination out-
side the intergenic region does allow the replicase to initi-
ate RNA synthesis; however, elongation is stalled at the
missing base. Therefore, PAP inhibits both the replicase
interaction with template RNA and its synthesis of new
RNA, thereby diminishing viral replication. Further work
will focus on how depurination within the intergenic
region alters its association with the replicase in vitro
and how this depurination may inhibit replicase assembly
in vivo.
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